Patents by Inventor Mark Ian Kemp

Mark Ian Kemp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds
    Patent number: 11958833
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the Invention include compounds having the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L and A are as defined herein.
    Type: Grant
    Filed: August 16, 2021
    Date of Patent: April 16, 2024
    Assignee: Mission Therapeutics Limited
    Inventors: Mark Ian Kemp, Martin Lee Stockley, Andrew Madin
  • 1-cyano-pyrrolidine derivatives as dub inhibitors
    Patent number: 11945797
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30).
    Type: Grant
    Filed: February 18, 2022
    Date of Patent: April 2, 2024
    Assignee: Mission Therapeutics Limited
    Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Michael David Woodrow
  • 1-(5-(2-CYANOPYRIDIN-4-YL)OXAZOLE-2-CARBONYL)-4-METHYLHEXAHYDROPYRROLO[3,4-B]PYR ROLE-5(1H)-CARBONITRILE AS USP30 INHIBITOR FOR USE IN THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION, CANCER AND FIBROSIS
    Publication number: 20230312580
    Abstract: The present invention relates to hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carbonitriles with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis:.
    Type: Application
    Filed: June 7, 2021
    Publication date: October 5, 2023
    Inventors: Christopher Andrew LUCKHURST, Mark Ian KEMP, Paul William THOMPSON, Martin Lee STOCKLEY
  • N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS
    Publication number: 20230303547
    Abstract: The present invention relates to a class of N-cyanopyrrolidines with activity as inhibitors of the deubiquity lating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis: (formulae (I)(i) and (I)(ii)).
    Type: Application
    Filed: June 3, 2021
    Publication date: September 28, 2023
    Inventors: Christopher Andrew LUCKHURST, Mark Ian KEMP, Paul William THOMPSON
  • N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION
    Publication number: 20230219939
    Abstract: The present invention relates to a class of N-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis: Formula (I), Formula (II).
    Type: Application
    Filed: May 27, 2021
    Publication date: July 13, 2023
    Inventors: Christopher Andrew LUCKHURST, Mark Ian KEMP, Paul William THOMPSON
  • N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS
    Publication number: 20230119013
    Abstract: The present invention relates to a class of N-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis.
    Type: Application
    Filed: April 7, 2021
    Publication date: April 20, 2023
    Inventors: Christopher Andrew LUCKHURST, Mark Ian KEMP, Paul William THOMPSON
  • NOVEL COMPOUNDS
    Publication number: 20230052191
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.
    Type: Application
    Filed: September 1, 2022
    Publication date: February 16, 2023
    Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin
  • Compounds
    Patent number: 11472798
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: October 18, 2022
    Assignee: MISSION THERAPEUTICS LTD
    Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin
  • SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS
    Publication number: 20220315572
    Abstract: The present invention relates to a class of substituted-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis: (I).
    Type: Application
    Filed: September 3, 2020
    Publication date: October 6, 2022
    Inventors: Paul William THOMPSON, Christopher Andrew LUCKHURST, Mark Ian KEMP
  • Sulfonamide-substituted cyanopyrrolidines with activity as DUB inhibitors
    Patent number: 11414402
    Abstract: The present invention relates to a class of sulfonamide-substituted cyanopyrrolidines of Formula (Ia) and (Ib) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase L1 (UCHL1) and ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction: (Formulae (Ia), (Ib)).
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: August 16, 2022
    Assignee: MISSION THERAPEUTICS LIMITED
    Inventors: Martin Lee Stockley, Mark Ian Kemp, Andrew Madin, Michael David Woodrow
  • Cyano-substituted heterocycles with activity as inhibitors of USP30
    Patent number: 11370784
    Abstract: The present invention relates to cyano-substituted-heterocycles of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: June 28, 2022
    Assignee: MISSION THERAPEUTICS LIMITED
    Inventors: Martin Lee Stockley, Mark Ian Kemp, Andrew Madin
  • 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS
    Publication number: 20220177451
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30).
    Type: Application
    Filed: February 18, 2022
    Publication date: June 9, 2022
    Inventors: Alison JONES, Mark Ian KEMP, Martin Lee STOCKLEY, Michael David WOODROW
  • 1-cyano-pyrrolidine derivatives as DUB inhibitors
    Patent number: 11352339
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30).
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: June 7, 2022
    Assignee: MISSION THERAPEUTICS LIMITED
    Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Michael David Woodrow
  • 4,6 dihydropyrrolo [3,4-C] pyrazole-5 (1H)-carbonitrile derivates for treating cancer
    Patent number: 11306096
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7). The invention further relates to the use of DUB or desumoylating inhibitors in the treatment of cancer. Described herein are compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c and R1d each independently represent hydrogen, optionally substituted C1-C6 alkyl or R1a and R1b together form an optionally substituted C3-C6 cycloalkyl ring, or R1c and R1d together form an optionally substituted C3-C6 cycloalkyl ring; A is a 5 membered nitrogen-containing aromatic ring and is substituted with at least one optionally substituted 5 to 10 membered monocyclic or bicyclic heteroaryl or aryl ring attached through an optional linker.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: April 19, 2022
    Assignee: MISSION THERAPEUTICS LIMITED
    Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Michael David Woodrow
  • Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors
    Patent number: 11236092
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of Cezanne 1. The invention further relates to the use of DUB inhibitors in the treatment of cancer.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: February 1, 2022
    Assignee: MISSION THERAPEUTICS LIMITED
    Inventors: Mark Ian Kemp, Martin Lee Stockley, Michael David Woodrow, Alison Jones
  • Novel Compounds
    Publication number: 20210380562
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the Invention include compounds having the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L and A are as defined herein.
    Type: Application
    Filed: August 16, 2021
    Publication date: December 9, 2021
    Inventors: Mark Ian KEMP, Martin Lee STOCKLEY, Andrew MADIN
  • Compounds
    Patent number: 11130748
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L and A are as defined herein.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: September 28, 2021
    Assignee: MISSION THERAPEUTICS LIMITED
    Inventors: Mark Ian Kemp, Martin Lee Stockley, Andrew Madin
  • CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30
    Publication number: 20210284631
    Abstract: The present invention relates to cyano-substituted-heterocycles of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction.
    Type: Application
    Filed: October 4, 2017
    Publication date: September 16, 2021
    Inventors: Martin Lee STOCKLEY, Mark Ian KEMP, Andrew MADIN
  • 1-cyano-pyrrolidine derivatives as inhibitors of USP30
    Patent number: 11091488
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylatin-enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, m, L and X are as defined herein.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: August 17, 2021
    Assignee: MISSION THERAPEUTICS LIMITED
    Inventors: Mark Ian Kemp, Martin Lee Stockley, Andrew Madin
  • Cyanopyrrolidine derivatives with activity as inhibitors of USP30
    Patent number: 11084821
    Abstract: The present invention relates to a class of substituted-cyanopyrrolidines of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: August 10, 2021
    Assignee: MISSION THERAPEUTICS LIMITED
    Inventors: Martin Lee Stockley, Mark Ian Kemp, Andrew Madin